6 – Milestone Announced in Non-Hodgkin’s Lymphoma Phase 2 Study of Daratumumab
Genmab A/S announced that it has reached a $5 million milestone in its collaboration with Janssen Biotech, Inc., in the Phase 2 study of Darzalex (daratumumab) as a potential treatment for non-Hodgkin’s lymphoma (NHL).
